Risk factors for kala-azar in Bangladesh

Emerging Infectious Diseases

Volumn 11, Issue 5, 2005, Pages 655-662

  Bern, Caryn ^a,c   Hightower, Allen W ^a   Chowdhury, Rajib ^b   Ali, Mustakim ^b   Amann, Josef ^a   Wagatsuma, Yukiko ^b   Haque, Rashidul ^b   Kurkjian, Katie ^a   Vaz, Louise E ^a   Begum, Moarrita ^b   Akter, Tangin ^b   Cetre Sossah, Catherine B ^a   Ahluwalia, Indu B ^a   Dotson, Ellen ^a   Secor, W Evan ^a   Breiman, Robert F ^a,b   Maguire, James H ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^c NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; BANGLADESH; CONFIDENCE INTERVAL; CONTROLLED STUDY; EDUCATION; FEMALE; HUMAN; INCOME; LEISHMANIA DONOVANI; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SEROLOGY; VISCERAL LEISHMANIASIS;

EID: 20944440741     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid1105.040718     Document Type: Article

References (23)

1. Desjeux P. Human leishmaniases: epidemiology and public health aspects. World Health Stat Q. 1992;45:267-75.
2. Murray CJL, Lopez AD, editors. Global health statistics: a compendium of incidence, prevalence, and mortality estimates for over 200 conditions. Vol. II. Boston: Harvard University Press; 1996.
3. Bora D. Epidemiology of visceral leishmaniasis in India. Natl Med J India. 1999;12:62-8.
4. Desjeux P. Leishmaniasis. Public health aspects and control. Clin Dermatol. 1996;14:417-23.
5. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis. 1997;24:684-703.
6. World Health Organization. Control of the leishmaniases. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1990;793:1-158.
7. National Health Policy - 2002. Government of India, Ministry of Health and Family Welfare. 2002 [cited 2005 Mar 7]. Available from http://mohfw.nic.in/ np2002.htm
8. Ahluwalia IB, Bern C, Costa C, Akter T, Chowdhury R, Ali M, et al. Visceral leishmaniasis: consequences of a neglected disease in a Bangladeshi community. Am J Trop Med Hyg. 2003;69:624-8.
9. Chappuis F, Rijal S, Singh R, Acharya P, Karki BM, Das ML, et al. Prospective evaluation and comparison of the direct agglutination test and an rK39-antigen-based dipstick test for the diagnosis of suspected kala-azar in Nepal. Trop Med Int Health. 2003;8:277-85.
10. Bern C, Jha SN, Joshi AB, Thakur GD, Bista MB. Use of the recombinant K.39 dipstick test and the direct agglutination test in a setting endemic for visceral leishmaniasis in Nepal. Am J Trop Med Hyg. 2000;63:153-7.
11. Houghton RL, Petrescu M, Benson DR, Skeiky YA, Scalone A, Badaro R, et al. A cloned antigen (recombinant K39) of Leishmania chagasi diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1 patients and a prognostic indicator for monitoring patients undergoing drug therapy. J Infect Dis. 1998;177:1339-44.
12. Karplus TM, Jeronimo SM, Chang H, Helms BK, Burns TL, Murray JC, et al. Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection. Infect Immun. 2002;70:6919-25.
13. Anstead GM, Chandrasekar B, Zhao W, Yang J, Perez LE, Melby PC. Malnutrition alters the innate immune response and increases early visceralization following Leishmania donovani infection. Infect Immun. 2001;69:4709-18.
14. Thakur CP. Socio-economics of visceral leishmaniasis in Bihar (India). Trans R Soc Trop Med Hyg. 2000;94:156-7.
15. Bern C, Joshi AB, Jha SN, Das ML, Hightower A, Thakur GD, et al. Factors associated with visceral leishmaniasis in Nepal: bed-net use is strongly protective. Am J Trop Med Hyg. 2000;63:184-8.
16. Kumar R, Kumar P, Chowdhary RK, Pai K, Mishra CP, Kumar K, et al. Kala-azar epidemic in Varanasi district, India. Bull World Health Organ. 1999;77:371-4.
17. Mukhopadhyay AK, Chakravarty AK. Bloodmeal preference of Phlebotomus argentipes & Ph. papatasi of north Bihar, India. Indian J Med Res. 1987;86:475-80.
18. Rees PH, Kager PA. Visceral leishmaniasis and post-kala-azar dermal leishmaniasis. In: Peters W, Killick-Kendrick R, editors. The leishmaniases in biology and medicine. Vol. II. London: Academic Press; 1987. p. 584-615.
19. Pearson RD, Jeronimo SMB, de Queiroz Sousa A. Leishmaniasis. In: Guerrant RL, Walker DH, Weller PF, editors. Tropical infectious diseases: principles, pathogens, and practice. Philadelphia: Churchill Livingstone; 1999. p. 797-813.
20. Reyburn H, Ashford R, Mohsen M, Hewitt S, Rowland M. A randomized controlled trial of insecticide-treated bednets and chaddars or top sheets, and residual spraying of interior rooms for the prevention of cutaneous leishmaniasis in Kabul, Afghanistan. Trans R Soc Trop Med Hyg. 2000;94:361-6.
21. Sundar S, Sahu M, Mehta H, Gupta A, Kohli U, Rai M, et al. Noninvasive management of Indian visceral leishmaniasis: clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit. Clin Infect Dis. 2002;35:581-6.
22. Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis. 2002;2:494-501.
23. Ganguly NK. Oral miltefosine may revolutionize treatment of visceral leishmaniasis. TDR News. 2002;68:2-3.